What is the metabolism and excretion process of Risperidone (risperidone) in patients, including those with impaired hepatic or renal function?

Metabolism and Excretion of Risperidone

Risperidone is extensively metabolized in the liver primarily by CYP2D6 to its equipotent active metabolite 9-hydroxyrisperidone (paliperidone), with both compounds eliminated predominantly via renal excretion (70% urine, 14% feces), requiring dose reduction in patients with severe renal or hepatic impairment. 1

Metabolism

Primary Metabolic Pathway

• Risperidone undergoes extensive hepatic metabolism via hydroxylation by CYP2D6 to form 9-hydroxyrisperidone, which has equivalent pharmacological activity to the parent compound 1
• The clinical effect results from the combined concentrations of risperidone plus 9-hydroxyrisperidone, not from risperidone alone 1, 2
• A minor metabolic pathway occurs through N-dealkylation 1

CYP2D6 Genetic Polymorphism

• CYP2D6 exhibits genetic polymorphism affecting approximately 6-8% of Caucasians and a very low percentage of Asians who are "poor metabolizers" with little to no enzyme activity 1
• Extensive metabolizers convert risperidone rapidly to 9-hydroxyrisperidone, while poor metabolizers convert it much more slowly 1
• Despite different individual component levels, the pharmacokinetics of the combined active moiety (risperidone + 9-hydroxyrisperidone) are similar between extensive and poor metabolizers after single and multiple doses 1, 3
• The half-life of risperidone is 3 hours in extensive metabolizers versus 20 hours in poor metabolizers, but the active fraction half-life is approximately 20 hours in both groups 1, 3

Enantioselective Metabolism

• CYP2D6 predominantly catalyzes formation of (+)-9-hydroxyrisperidone, the major metabolic pathway under clinical conditions 4
• CYP3A4/3A5 catalyzes formation of (-)-9-hydroxyrisperidone at lower rates 4
• The (+)-enantiomer concentration is higher than the (-)-enantiomer in extensive metabolizers 4

Excretion

Routes of Elimination

• Risperidone and its metabolites are eliminated 70% via urine and 14% via feces, with total recovery of radioactivity reaching 84% at one week 1
• Less than 1% is excreted unchanged in feces 3

Half-Life Characteristics

• The apparent half-life of 9-hydroxyrisperidone is approximately 21 hours in extensive metabolizers and 30 hours in poor metabolizers 1
• The overall mean elimination half-life of the active fraction is about 20 hours regardless of metabolizer status 1
• Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and approximately 5 days in poor metabolizers 1
• Steady-state concentrations of 9-hydroxyrisperidone are reached in 5-6 days 1

Special Populations Requiring Dose Adjustment

Renal Impairment

• Patients with severe renal impairment require dose reduction, with risperidone started at 0.5 mg PRN and titrated cautiously 5, 6
• Renal clearance of both risperidone and 9-hydroxyrisperidone is decreased in renal impairment 1
• The active fraction is primarily eliminated renally, making accumulation a significant concern 1

Hepatic Impairment

• Patients with severe hepatic impairment require dose reduction 5
• Risperidone is extensively metabolized in the liver, making hepatic dysfunction clinically significant 1
• Dose reduction is necessary in patients with severe liver dysfunction 5

Elderly Patients

• In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone is decreased and elimination half-lives are prolonged compared to young healthy subjects, requiring dose modification 1
• Lower starting doses (0.25-0.5 mg) should be used in older or frail patients with gradual titration 5

Drug Interactions Affecting Metabolism

CYP2D6 Inhibitors

• Potent CYP2D6 inhibitors like quinidine interfere with conversion of risperidone to 9-hydroxyrisperidone, giving recipients a pharmacokinetic profile typical of poor metabolizers 1
• Terbinafine, a CYP2D6 inhibitor, can significantly alter the risperidone to 9-hydroxyrisperidone ratio and prolong clinical response to dose changes 7
• Monitoring for increased extrapyramidal symptoms and excessive sedation is required when using CYP2D6 inhibitors 8

CYP3A4 Inducers

• Co-administration of enzyme inducers (carbamazepine, phenytoin, rifampin, phenobarbital) causes a decrease in combined plasma concentrations of risperidone and 9-hydroxyrisperidone 1
• Drugs affecting CYP3A activity can result in at least a 2-fold decrease or increase in plasma risperidone levels 9

CYP3A4 Inhibitors

• Ketoconazole strongly inhibits formation of (-)-9-hydroxyrisperidone 4
• Powerful CYP3A inhibitors can result in at least a 2-fold increase in plasma risperidone levels 9

Clinical Implications

Bioavailability and Absorption

• The absolute oral bioavailability of risperidone is 70%, with rapid absorption and peak plasma concentrations occurring at approximately 1 hour 1, 2
• Food does not affect the rate or extent of absorption, allowing administration with or without meals 1

Distribution

• Risperidone is rapidly distributed with a volume of distribution of 1-2 L/kg 1
• Plasma protein binding is 90% for risperidone and 77% for 9-hydroxyrisperidone 1

Monitoring Considerations

• Plasma level monitoring may be useful in clinical settings, especially when patients take multiple medications or CYP2D6 deficiency is suspected 9
• The stable relationship between daily doses and total plasma concentration (risperidone plus 9-hydroxyrisperidone) supports therapeutic drug monitoring 9
• The ratio between risperidone and 9-hydroxyrisperidone characterizes CYP2D6 metabolizer status 9